Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.

bioRxiv : the preprint server for biology·2023
Same author

Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same author

Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same author

Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.

Cancer research·2022
Same author

Molecular evidence for the occurrence of <i>Pumpkin yellows virus</i> (PuYV), a new polerovirus species associated with pumpkin plants.

Virusdisease·2022

Related Experiment Video

Updated: Jun 8, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Delivering nanomedicine to solid tumors.

Rakesh K Jain1, Triantafyllos Stylianopoulos

  • 1Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA. jain@steele.mgh.harvard.edu

Nature Reviews. Clinical Oncology
|September 15, 2010
PubMed
Summary

Nanoparticles show promise for cancer treatment, but tumor barriers hinder uniform delivery. Overcoming these physiological barriers is crucial for effective nanomedicine in patients.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Related Experiment Videos

Last Updated: Jun 8, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Area of Science:

  • Oncology
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Nanotechnology offers potential for cancer detection, prevention, and treatment.
  • The enhanced permeability and retention (EPR) effect is a key rationale for nanoparticle use in solid tumors.
  • However, uniform nanoparticle delivery to all tumor regions remains a significant challenge.

Purpose of the Study:

  • To review the physiological barriers limiting nanoparticle delivery to solid tumors.
  • To summarize strategies developed to overcome these delivery barriers.
  • To discuss design considerations for optimizing nanoparticle delivery to tumors.

Main Methods:

  • Literature review of nanotechnology in cancer therapy.
  • Analysis of physiological barriers in tumor microenvironments.
  • Summary of current strategies to enhance nanoparticle delivery.

Main Results:

  • Tumor vasculature and interstitial matrix present significant physiological barriers.
  • Heterogeneous distribution of therapeutics results from these barriers.
  • These barriers contribute to the modest survival benefit of current nanotherapeutics.

Conclusions:

  • Overcoming physiological barriers is essential for realizing the full potential of nanomedicine.
  • Strategic design of nanoparticles is critical for effective tumor targeting.
  • Future nanomedicine development must address delivery challenges for improved patient outcomes.